NFXBio: Why C2i is the World’s First Platform for Cancer Intelligence
In this episode, James Currier and Omri Amirav-Drory delve into synthetic biology and tech bio, introducing guest Asaf Zviran, CEO of C2I. They discuss the impact of tech bio on industries, strategies for hiring and fundraising in a virtual world, and the balance between science and business in startups. They also explore the future of cancer treatment and provide valuable advice for startup founders.
Key Points
- C2I Genomics is revolutionizing cancer treatment by using a platform that detects and monitors cancer from blood samples, providing real-time data to optimize treatment decisions.
- The NFX Bio investment thesis focuses on tech bio platforms that combine biology and technology, enabling the creation of diverse products across huge markets like therapeutics, diagnostics, and renewable energy.
- Scientific founders transitioning to startup CEOs bring valuable skills such as the ability to learn quickly, design experiments, and possess the grit necessary to persevere through the challenges of startup growth.
The team at C2i Genomics is combining cutting-edge genomics and sophisticated AI to provide the world’s first whole-genome cancer intelligence platform, transforming the way cancer is monitored and treated.
C2i uses a blood test that can detect and quantify tiny amounts of residual cancer to better monitor cancer treatment, progression, and recurrence. NFX was an early stage investor in C2i due to their long-term vision and world-changing technology.
Listen to NFX Partner Omri Amirav-Drory talk with Asaf Zviran, Co-founder & CEO of C2i Genomics, about the future of their company, their latest technological breakthroughs, and where the industry is headed in the near future.
Asaf and Omri's conversation begins at 11:15
Visit C2i to learn more - https://c2i-genomics.com/
Chapters
| 0:00 | |
| 1:24 | |
| 3:03 | |
| 6:28 | |
| 11:18 | |
| 25:23 | |
| 29:43 | |
| 31:20 | |
| 38:07 | |
| 41:46 | |
| 44:51 | |
| 48:25 |
Transcript
Loading transcript...